Tissue Repair During Acute Phase of Myocardial Infarction

心肌梗塞急性期的组织修复

• 批准号: 8001063
• 负责人: Manley TF Huang
• 金额: $ 23.06万
• 依托单位: PANORAMA RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-20 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8001063
• 关键词: Acute; Acute myocardial infarction; Affect; Alternative Therapies; Apoptosis; Atherosclerosis; Binding; Binding Sites; Biochemical; Biological; Bone Marrow; Cardiac; Cardiac Myocytes; Cardiovascular Diseases; Cell Death; Cells; Chimera organism; Chimeric Proteins; Chronic; Cicatrix; Clinical; Developed Countries; Development; Dose; Drug Kinetics; Event; Fibrosis; Goals; Growth; Growth Factor; Half-Life; Heart; Heart Transplantation; Heart failure; Heme; Hepatocyte Growth Factor; Heterodimerization; Hour; Human; IgG1; Immune response; Infarction; Inflammation; Inflammatory; Intervention; Ischemia; Kidney; Kidney Failure; Link; Liver; Liver Cirrhosis; Liver Fibrosis; MSP subunit photosystem II; Morbidity - disease rate; Morphology; Myocardial; Myocardial Infarction; Myocardial Ischemia; Myocardial tissue; Myocardium; Natural regeneration; Necrosis; Neoplasm Metastasis; Organ; Oxidases; Pathway interactions; Patients; Pharmacodynamics; Phase; Plasma; Process; Production; Proteins; Quality of life; Recombinants; Recovery; Reperfusion Therapy; Rodent Model; Role; Route; Signal Transduction; Staging; Stem cells; Testing; Therapeutic; Therapeutic Agents; Time; Tissues; Toxicology; United States; Up-Regulation; Wound Healing; acute coronary syndrome; angiogenesis; base; chemotherapy; clinical application; cytokine; design; design and construction; heart function; human MST1R protein; improved; macrophage stimulating protein; meetings; mortality; novel; polypeptide; prevent; public health relevance; receptor; thrombolysis; tissue regeneration; tumor; tumor growth

DESCRIPTION (provided by applicant): Tissue Repair During Acute Phase of Myocardial Infarction Cardiovascular disease is the leading cause of mortality and morbidity in developed countries. Each year, over 19 million incidents of sudden cardiac events occur worldwide, with approximately 1 million of those in the United States. Patients with acute coronary syndrome (ACS) suffer from a range of acute myocardial ischemic states. Thrombolysis and percutaneous intervention (PCI) are used to reperfuse the ischemic tissue and stabilize damage caused by infarction. After acute myocardial infarction (AMI), affected ischemic tissues undergo cell death from necrosis and apoptosis, followed by inflammation and a process of granulation leading to scar tissue formation. The period immediately following AMI provides a critical and unique opportunity to rescue damaged myocardial tissues and prevent fibrosis. The goal of this project is to develop a novel protein based therapy to rescue heart tissue from apoptosis, reduce inflammation and fibrosis, and restore cardiac function after AMI. PUBLIC HEALTH RELEVANCE: Tissue Repair During Acute Phase of Myocardial Infarction Cardiovascular disease is the leading cause of mortality and morbidity in developed countries. Acute myocardial infarction (AMI) affects 19 million people worldwide, with a large number suffering from heart failure. To goal of this project is to develop a novel therapy that will significantly enhance the recovery of heart function after AMI and thereby greatly reduce the level of mortality while improving quality of life of affected patients.

描述(由申请人提供)：心肌梗死急性期的组织修复心血管疾病是发达国家死亡率和发病率的主要原因。每年，全世界发生超过1900万起突发心脏事件，其中大约100万起发生在美国。急性冠脉综合征(ACS)患者患有一系列急性心肌缺血状态。溶栓治疗和经皮介入治疗(PCI)是用来对缺血组织进行再灌注，以稳定脑梗塞造成的损害。急性心肌梗死(AMI)后，受影响的缺血组织因坏死和凋亡而发生细胞死亡，随后是炎症和肉芽形成过程，导致瘢痕组织形成。急性心肌梗死后的这段时间为抢救受损的心肌组织和预防纤维化提供了一个关键而独特的机会。该项目的目标是开发一种新的基于蛋白质的治疗方法，以挽救心肌组织的凋亡，减少炎症和纤维化，并恢复急性心肌梗死后的心功能。 公共卫生相关性：心肌梗死急性期的组织修复心血管疾病是发达国家死亡率和发病率的主要原因。急性心肌梗死(AMI)影响着全球1900万人，其中大量人患有心力衰竭。本项目的目标是开发一种新的治疗方法，显着促进急性心肌梗死后心功能的恢复，从而大大降低死亡率水平，同时提高患者的生活质量。